Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
synthetic lethality
Biotech
Tango axes PRMT5 inhibitor, shifts focus to 2 sibling molecules
Tango has shuffled TNG908 off the dance floor, halting enrollment in a study of the cancer drug candidate to focus on two related molecules.
Nick Paul Taylor
Nov 6, 2024 8:28am
Repare lays off 25% of staff as biotech halts preclinical R&D
Aug 29, 2024 6:36am
Ideaya bags option on Biocytogen bispecific ADC in $400M deal
Jul 31, 2024 9:04am
Tango drops USP1 inhibitor over liver toxicity in phase 1 trial
May 23, 2024 8:11am
Roche axes Repare's oncology drug days after starting study
Feb 13, 2024 5:51am
Merck inks $169M PARP1 deal, escalating challenge to AstraZeneca
Oct 30, 2023 8:40am
